Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation

MD Murphey, MJ Minn, AL Contreras, KK Koeller… - Skeletal radiology, 2023 - Springer
Benign notochordal cell tumor (BNCT) and chordoma are neoplasms of notochordal
differentiation. BNCT represents notochordal rests, commonly an incidental lesion present in …

Lymphocyte infiltration score and spatial characteristics refined the prognosis and denosumab treatment responsiveness indicators for giant cell tumor of bone

HL Wu, C Xia, FS Liu, BY Zheng, HQ Niu… - JCO Precision …, 2024 - ascopubs.org
PURPOSE The prognostic value of lymphocyte infiltration score (LIS) and its nearest
neighbor distance to tumor cells (NNDTC) in giant cell tumor of bone (GCTB) is currently not …

The tumor-stroma ratio in giant cell tumor of bone: associations with the immune microenvironment and responsiveness to denosumab treatment

HL Wu, XB Wang, J Li, BW Zheng - Journal of Orthopaedic Surgery and …, 2024 - Springer
Background Currently, there is limited understanding regarding the clinical significance of
the tumor-stroma ratio (TSR) in giant cell tumor of bone (GCTB). Hence, we aimed to …

De novo Versus Secondary Dedifferentiated Chordomas: A Population-Based Analysis and Integrated Individual Participant Data Meta-Analysis

HG Vuong, MK Le, TPX Nguyen, K Eschbacher - World neurosurgery, 2023 - Elsevier
Objective There is a lack of data about the clinicopathological and molecular characteristics
of de novo versus secondary dedifferentiated chordoma (DC). This integrated study aimed to …

Clinicopathologic and prognostic characteristics of tumor budding‐like in giant cell tumor of bone

BW Zheng, BY Zheng, Z Yang, HQ Niu, GQ Zhu… - Cancer, 2024 - Wiley Online Library
Background Currently, tumor budding (TB) is defined as an important factor for a poor
prognosis in various types of cancers. The authors identified a significant presence of TB …

[HTML][HTML] Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients

C Xia, W Huang, YL Chen, HB Fu, M Tang… - Frontiers in …, 2022 - frontiersin.org
Background Immunotherapy only achieves efficacy in some cancer patients, and less is
known about other immune checkpoint molecules in chordoma. Here, we aimed to …

Immunohistochemical markers predicting recurrence following resection and radiotherapy in chordoma patients: insights from a multicenter study [RETRACTED]

AB Nieves, AK Ghaith, VG El-Hajj, OO Akinduro… - Journal of …, 2023 - thejns.org
OBJECTIVE Chordomas are rare tumors that often recur regardless of surgery with negative
margins and postoperative radiotherapy. The predictive accuracy of widely used …

[HTML][HTML] Incidence and centralization of chordoma in the Netherlands: A nationwide study between 1991 and 2020

A Lipplaa, RJP van der Wal, ADG Krol, WC Peul… - Cancer …, 2024 - Elsevier
Introduction Chordomas are rare malignant bone tumors arising in the axial skeleton, with
an incidence of 0.3–0.88 per million inhabitants. We studied the annual incidence rate and …

[HTML][HTML] Poorly differentiated chordoma

L Yang, Y Liu, Y Tang, J Wei, L Fan, Y Wang… - Human Pathology …, 2022 - Elsevier
Chordoma is a rare primary malignant bone tumor that is believed to develop from
embryonic notochordal remnants. The current World Health Organization (WHO) …

Poorly differentiated chordoma: recognising this complex and rare aggressive tumour with characteristic immunohistochemical profile

A Goyal, K Shah, AM Uppar, N Bn - Child's Nervous System, 2024 - Springer
Introduction Poorly differentiated chordoma (PDC) is an uncommon subtype of chordoma,
distinct in its occurrence in paediatric age group, location, variable epithelioid/rhabdoid …